InsiderSignal.AI

InsiderSignal.ai

AARD - Aardvark Therapeutics, Inc.

Insider Purchase by Sun Nelson (CFO)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Sun Nelson, serving as CFO at Aardvark Therapeutics, Inc. (AARD), purchased 6,000 shares at $8.07 per share, for a total transaction value of $48,440.00. Following this transaction, Sun Nelson now holds 105,484 shares of AARD.

This purchase represents a 6.00% increase in Sun Nelson's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, September 9, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, September 10, 2025, 1 day after the trade was made.

Aardvark Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Sun Nelson

CFO

Nelson Sun is the Chief Financial Officer (CFO) of Aardvark Therapeutics, Inc. (NASDAQ: AARD), a biopharmaceutical company developing therapies for metabolic and inflammatory diseases.[[1]](https://theorg.com/org/aardvark-therapeutics/org-chart/nelson-sun)[[3]](https://aardvarktherapeutics.com/team/)[[7]](https://www.gurufocus.com/news/4068583/insider-buying-nelson-sun-acquires-additional-shares-of-aardvark-therapeutics-inc-aard) He recently purchased 3,000 shares of AARD on December 11, 2025, at $14.4 per share, totaling $43,200, bringing his direct ownership to 108,484 shares.[[2]](https://www.investing.com/news/insider-trading-news/sun-nelson-cfo-buys-aardvark-therapeutics-shares-worth-43200-93CH-4407002)[[4]](https://longbridge.com/en/news/269582546)[[7]](https://www.gurufocus.com/news/4068583/insider-buying-nelson-sun-acquires-additional-shares-of-aardvark-therapeutics-inc-aard) Sun brings over 20 years of experience in financial management, business operations, and corporate strategy.[[3]](https://aardvarktherapeutics.com/team/) Prior to Aardvark, he served as Operating Partner at Dubilier & Company, assessing underperforming assets and providing executive oversight to portfolio companies, and as Vice President at Valor Equity Partners, focusing on M&A, portfolio management, and operations.[[1]](https://theorg.com/org/aardvark-therapeutics/org-chart/nelson-sun)[[3]](https://aardvarktherapeutics.com/team/) Earlier roles include Vice President and Counsel at NantWorks and Abraxis BioScience, and Counsel, Corporate Development at American Pharmaceutical Partners.[[3]](https://aardvarktherapeutics.com/team/) He holds an MBA in Finance from The Wharton School and an MA in International Studies from the University of Pennsylvania.[[1]](https://theorg.com/org/aardvark-therapeutics/org-chart/nelson-sun)

View full insider profile →

Trade Price

$8.07

Quantity

6,000

Total Value

$48,440.00

Shares Owned

105,484

Trade Date

Tuesday, September 9, 2025

166 days ago

SEC Filing Date

Wednesday, September 10, 2025

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Aardvark Therapeutics, Inc.

Company Overview

No company information available
View news mentioning AARD

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/277620

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime